Baxter International Inc. is a healthcare company that provides a portfolio of essential medical products, devices, and pharmaceuticals. The company operates through three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Its product portfolio includes sterile intravenous solutions, infusion systems, parenteral nutrition therapies, surgical hemostats and sealants, smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, inhaled anesthetics, and generic injectable pharmaceuticals. Baxter serves hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home. Incorporated in 1931, the company manufactures and sells its products globally. Baxter recently completed the sale of its Kidney Care business, now known as Vantive Health LLC, and its BioPharma Solutions business. The company focuses on connected care solutions and core therapy offerings to support healthcare delivery across various settings.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage baxter.com
Sector Healthcare IR page investor.baxter.com/investors/investor-overview/default.aspx
Tags
intravenous solutions, infusion systems, parenteral nutrition, surgical hemostats, smart bed systems, patient monitoring, respiratory health devices, injectable pharmaceuticals, inhaled anesthetics, connected care, Vantive Health LLC, Baxter Growth and Performance system
Press page investor.baxter.com/investors/events-and-news/news/default.aspx

Metrics

Valuation  
Market cap $ 12.416B
Market cap (USD) $ 12.416B
P/E -19.67
PEG —
P/BV 1.91
P/S 1.07
P/OCF 7.57
P/FCF 37.40
Dividend yield 0.17%
Turnover / mcap —
Returns  
ROE -14.6%
ROI -6.1%
ROIC -1.5%
Profit margin -8.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 154.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -42.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 11.244B 10.636B 14.813B 15.113B 12.784B 11.673B 11.362B 11.127B 10.561B 10.163B 9.968B 16.671B 15.259B 14.19B 13.893B 12.843B 12.562B 12.348B 11.263B 10.378B 9.849B 9.509B 8.916B 8.11B 7.663B 6.896B 6.38B 5.706B
Net profit -957M -649M 2.656B -2.433B 1.284B 1.102B 1.001B 1.624B 717M 4.965B 968M 2.497B 2.012B 2.326B 2.224B 1.42B 2.205B 2.014B 1.707B 1.397B 956M 388M 881M 778M 612M 740M 797M 315M
Free cash flow 332M 573M 1.034B 532M 1.479B 1.159B 1.408B 1.415B 1.203B 935M 736M 1.317B 1.673B 1.945B 1.857B 2.04B 1.895B — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Share price 19.11 29.16 38.66 50.97 85.84 80.24 83.62 65.82 64.64 44.34 38.15 73.29 69.55 66.66 49.48 50.62 58.68 53.59 58.55 46.1 — — — — — — — —
Price performance 12m -0.34 -0.25 -0.24 -0.41 0.07 -0.04 0.27 0.02 0.46 0.16 -0.48 0.05 0.04 0.35 -0.02 -0.14 0.09 -0.08 0.27 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 1.84B 1.9B 2.08B 2.63B 2.66B 2.69B 1.68B 1.86B
↳ YoY growth +3.0% +9.5% +26.6% +1.1% +1.2% -37.6% +10.8%
↳ 5y CAGR +7.9% -2.4% -2.2%
Borrowings, current (USD) 0.00 3M 2M 226M 0.00 301M 299M 0.00 2.13B 1M
Borrowings, non-current (USD) 2.78B 3.51B 3.47B 4.81B 5.79B 17.1B 15.2B 11.1B 10.4B 9.47B
Lease liabilities (USD) — — 502M 665M 677M 720M 641M 635M 344M 327M
Cash and deposits (USD) 2.8B 3.39B 1.83B 3.34B 3.73B 2.95B 1.72B 3.19B 1.76B 1.97B
Intangible assets (USD) 1.11B 1.37B 1.4B 1.47B 1.67B 7.79B 6.79B 6.08B 5.22B 4.37B
Right-of-use assets (USD) — — — 608M 603M 630M 550M 524M 306M 276M
Net debt (borrowings + leases - cash) (USD) -22M 118M 1.64B 2.37B 2.73B 15.2B 14.5B 8.57B 11.1B 7.84B
Cash flow detail
Operating cash flow (USD) 1.65B 1.84B 2.1B 2.1B 1.87B 2.22B 1.21B 1.73B 1.02B 845M
Purchases of property, plant and equipment (USD) -719M -634M -681M -696M -709M -743M -679M -692M -446M -513M
Change in receivables (cash effect) (USD) 15M 30M -12M -65M -126M -170M -146M -66M -35M -132M
Change in inventories (cash effect) (USD) 80M 76M -197M 4M -162M -37M -361M -114M -201M -119M
Change in payables (cash effect) (USD) -197M 84M 53M -212M 143M 104M -76M 107M 112M 3M
Dividends paid (cash effect) (USD) -268M -315M -376M -423M -473M -530M -573M -586M -590M -348M
Share buybacks (cash effect) (USD) -292M -564M -2.45B -1.27B -500M -600M -32M 0.00 0.00 —
Interest paid (cash effect) (USD) -99M -80M -94M -103M -137M -145M -355M -484M -401M -303M
Income taxes paid (cash effect) (USD) -500M -255M -302M -294M -249M -282M -330M -262M -223M -222M
Share-based compensation (USD) 115M 107M 115M 122M 130M 146M 154M 133M 114M 117M
Operating cash flow before change in receivables (USD) 1.64B 1.81B 2.11B 2.17B 1.99B 2.39B 1.36B 1.79B 1.05B 977M
Free cash flow (OCF - PPE - intangibles) (USD) 935M 1.2B 1.42B 1.41B 1.16B 1.48B 532M 1.03B 573M 332M
Income detail
Research and development expense (USD) 647M 617M 655M 595M 521M 534M 605M 667M 590M 518M
↳ 5y CAGR -7.3% -11.8% -12.1% -16.0% -2.9% -3.8% -0.4% +0.4% -0.2% -0.1%
Total comprehensive income (USD) 185M 1.27B 1.2B 1.29B 1.51B 1.23B -2.88B 2.94B -1.11B -701M
Comprehensive income to owners (USD) — 1.32B 1.27B 1.28B 1.5B 1.22B -2.88B 2.94B -1.11B -701M
Provision for credit losses (USD) — — — 12M 11M -2M -7M -16M -7M 6M
Credit cost ratio (credit losses / average receivables) (%) — — — 0.6% 0.6% 0.1% 0.3% 0.6% 0.3% 0.3%
Reported Feb 23, 2017 Mar 17, 2020 Mar 17, 2020 Feb 11, 2021 Feb 11, 2021 Feb 23, 2022 Feb 9, 2023 Feb 8, 2024 Feb 21, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Baxter Reports Third-Quarter 2026 Results Bull 4 Bear 0 Results

October 29, 2026

  • Third-quarter sales of $2.98 billion increased 5% on both a reported and organic basis,1, 2 reflecting growth in all segments and divisions
  • Third-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.57; adjusted diluted EPS of $0.581
  • Company raises full-year 2026 financial outlook

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026.

“We delivered a strong third quarter, with growth across all segments and divisions globally,” said Andrew Hider, president and CEO. “We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger foundation for sustainable growth and long-term value creation.”

Third-Quarter 2026 Companywide Financial Results

Unless otherwise noted, all financial results reflect continuing operations and exclude Baxter’s former Kidney Care business, which is reported as discontinued operations.

  • Worldwide sales in the third quarter totaled approximately $2.98 billion, increasing 5% on both a reported and organic basis.
  • U.S. sales in the third quarter totaled approximately $1.6 billion, increasing 3% on a reported basis and 5% on an organic basis.
  • International sales in the third quarter totaled approximately $1.4 billion, increasing 7% on a reported basis and 6% on an organic basis.
  • On a U.S. GAAP basis, net income totaled $298 million, or $0.57 per diluted share.
  • On an adjusted basis, net income in the third quarter was $0.58 per diluted share, decreasing 16% due to a higher effective tax rate, year-over-year.
  • Free cash flow was $448 million in the third quarter and totaled $705 million year-to-date.
  • During the third quarter, the company completed a $600 million cash tender offer , retiring $864 million of debt and accelerating deleveraging while supporting its investment-grade credit objectives.

Please see the attached schedules accompanying this press release for additional details on sales performance in the quarter, including breakouts by Baxter’s segments.

Third-Quarter 2026 Segment Results

Beginning in the second quarter of 2026, Baxter updated its segment reporting structure to align with changes to the company’s operating model.4 Previously reported segment results have been recast to conform to the updated reporting structure and are available on the Investor Relations section at www.baxter.com . In the third quarter, growth continued across all segments and divisions.

  • Medical Products & Therapies sales for the third quarter totaled approximately $2.1 billion, increasing 6% on both a reported and organic basis. Performance in the quarter reflected strength within the Infusion Therapies & Platforms division, driven primarily by Infusion Systems, Drug Compounding and IV Solutions. This growth was partially offset by reduced sales within Injectables. Continued strong global demand for Advanced Surgery products also contributed to performance.
  • Healthcare Systems & Technologies sales for the third quarter totaled approximately $806 million, increasing 4% on both a reported and organic basis. Performance in the quarter reflected strong demand for Care & Connectivity Solutions products, driven by growth in Global Surgical Solutions and Patient Support Systems. Results also reflected growth in Front Line Care.

Full-Year 2026 Financial Outlook

The company raised its full-year financial outlook:

  • Reported sales growth from continuing operations: 4% to 5% (previously 3% to 4%)
  • Organic sales growth from continuing operations: 3% to 4% (previously 2% to 3%)
  • Adjusted earnings from continuing operations per diluted share: $2.05 to $2.15 (previously $1.95 to $2.15)

See the "Non-GAAP Financial Measures" section for explanations of the company’s non-GAAP financial measures.

Earnings Conference Call

Baxter will host a conference call today, Oct. 29, 2026, at 7:30 a.m. CDT to discuss its third-quarter 2026 results and provide an update on the business. The conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com . Please see www.baxter.com

Published Date: 7 Oct 2026

Published Location:

DEERFIELD, Ill.

Download PDF Copy link

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. 

To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.

This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com . The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.
 

About Baxter 

At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X , LinkedIn and Facebook .

Baxter

©Copyright 2026 Baxter. All rights reserved.

Published Date: 30 Sep 2026

Published Location:

DEERFIELD, Ill.

  • Explores how healthcare organizations can maximize the impact of technology investments
  •  Introduces a four-stage technology maturity framework to help hospitals benchmark progress and identify areas to prioritize

Download PDF Copy link

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report , offering new insights into how hospitals across the United States are leveraging technology investments to drive clinical and operational outcomes.

Based on a survey of 150 information technology (IT) and nursing leaders, the report examines how hospitals are progressing along a "connected hospital" journey by identifying four distinct levels of technology maturity (early, developing, advancing and leading). This framework is designed to help hospitals benchmark progress, prioritize initiatives that reflect their current needs and opportunities, and identify practical focus areas to strengthen long-term impact. The report reflects Baxter’s broader focus on helping healthcare organizations create more connected, data-informed care environments. 

"Hospitals continue to invest in technology, yet many are still working to achieve measurable outcomes," said Rob Kraal, vice president, Connected Care at Baxter. "This report provides an actionable framework to help hospital leaders understand where they are today and focus on initiatives that can translate connected technologies into meaningful impact."

Key insights from the report include:

  • Technology is critical, but progress varies: While 89% of hospitals say technology investments are essential to future growth, only 53% believe they are maximizing the impact of those investments.
  • Three health technology priorities rise above the rest: Hospitals across all maturity levels are focusing investments on operational efficiency, workflow automation and data integration as they work to strengthen operations and improve clinical outcomes.
  • Automation is a key marker of progress: Adoption of workflow automation increases significantly with maturity, from 18% of early-stage hospitals to 72% of leading organizations. 
  • Security and change management remain key barriers: Across all maturity levels, security risks and workforce adoption challenges are among the top obstacles to successfully deploying new technologies.

As many healthcare organizations continue to embrace artificial intelligence (AI) and other advanced technologies, the report reinforces the importance of a connected foundation. Ninety-five percent of respondents agree that future innovation will require stronger integration among core IT systems, medical devices and software applications, underscoring the role of connected data and workflows in helping hospitals effectively adopt and scale new capabilities.

The 2026 Connected Hospital Report provides healthcare leaders with a structured view of the opportunities and challenges shaping digital transformation in hospitals. To read the full report and learn more about Baxter’s connected care solutions, visit Baxter.com .

About Baxter

At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician’s office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X , LinkedIn and Facebook .

Baxter is a registered trademark of Baxter International Inc. or its subsidiaries.

Baxter

©Copyright 2026 Baxter. All rights reserved.

Prompts

Baxter International Inc. (ticker BAX), listed in United States.

ETFs Holding Baxter International Inc.

ETF Weight in ETF Shares Market value As of
FPAG 1.37% 348,271 $ 7.425M Jun 30, 2026
BLCV 1.24% 173,959 $ 4.443M Nov 16, 2026
CVGD 1.17% 61,914 $ 1.62M Jul 31, 2026
RCGE 0.53% 20,391 $ 530K Nov 18, 2026
FFLC 0.50% 230,785 $ 6.037M Jul 31, 2026
ITAN 0.50% 23,994 $ 618.085K Nov 17, 2026
ABCS 0.49% 2,337 $ 60.762K Aug 31, 2026
BTAL short -0.42% -55,154 $ -1.176M Jun 30, 2026
AVMC 0.16% 34,379 $ 878.04K Nov 16, 2026
DFAS 0.15% 1,984,842 $ 51.09M Nov 12, 2026
FTLS short -0.09% -92,201 $ 0.00 Nov 16, 2026
INRO 0.09% 21,786 $ 556.414K Nov 16, 2026
SHRT 0.07% 357 $ 9,117.78 Nov 17, 2026
DFAT 0.06% 754,872 $ 19.43M Nov 12, 2026
DFSV 0.06% 627,719 $ 16.157M Nov 12, 2026
CAPE 0.05% 5,604 $ 119.477K Jun 30, 2026
AAUS 0.05% 10,513 $ 270K Nov 18, 2026
MKTN 0.05% 2,380 $ 50.742K Jun 30, 2026
DXUV 0.04% 98,284 $ 2.53M Nov 12, 2026
LGDX 0.04% 2,177 $ 55.601K Nov 17, 2026
AVLC 0.03% 20,693 $ 528.499K Nov 16, 2026
JSTC 0.03% 3,126 $ 79.838K Nov 17, 2026
DCOR 0.03% 451,754 $ 11.628M Nov 12, 2026
DFAU 0.02% 112,204 $ 2.888M Nov 12, 2026
AVUS 0.02% 88,344 $ 2.256M Nov 16, 2026
AVSU 0.02% 2,955 $ 75.471K Nov 16, 2026
DFUS 0.02% 165,553 $ 4.261M Nov 12, 2026
HCMT 0.02% 3,599 $ 94.15K Jul 31, 2026
DFAC 0.02% 536,265 $ 13.803M Nov 12, 2026
DFUV 0.01% 87,821 $ 2.261M Nov 12, 2026
GSPY 0.01% 1,833 $ 46.815K Nov 17, 2026
EBI 0.00% 497 $ 12.922K Aug 31, 2026
CSHP 0.00% 736 $ 18.797K Nov 16, 2026
IALT short 0.00% -219 $ -5,593.26 Nov 16, 2026
CORO 0.00% 326 $ 8,329.20 Nov 16, 2026
NTRL short 0.00% -3,152 $ 0.00 Nov 16, 2026